Press Releases Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
26.22 ^USD	+7.41%		+8.26%	+232.32%

May. 31	Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	CI
May. 20	Transcript : Jasper Therapeutics, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	May. 30	AQ
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference	May. 29	AQ
Jasper Therapeutics : Corporate Presentation May 2024	May. 20	PU
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments	May. 14	AQ
Jasper Therapeutics : Corporate Presentation May 2024	May. 13	PU
Jasper Therapeutics Announces Briquilimab Development Program in Asthma	May. 13	AQ
Jasper Therapeutics to Present at Upcoming Investor Conferences in May	May. 07	AQ
Jasper Therapeutics : Corporate Presentation April 2024	Apr. 16	PU
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	AQ
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 21	AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	Mar. 19	AQ
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	Mar. 15	AQ
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	Mar. 04	AQ
Jasper Therapeutics : Corporate Presentation March 2024	Mar. 04	PU
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	Feb. 26	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	Feb. 26	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting	Feb. 23	AQ
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference	Feb. 07	AQ
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock	Feb. 06	AQ
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	Feb. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Press Releases

Filters